Nanovaccine Platform Technology: A New Paradigm

Balaji Narasimhan

Department of Chemical and Biological Engineering

Presented by: Sarah A. Rajala, Dean, College of Engineering

IOWA STATE UNIVERSITY
Why the Urgency?

- Re-emergence of known diseases and rapid emergence of new diseases
- Need to improve existing vaccines (e.g., 2012-13 influenza vaccine)
- Antibiotic resistance
- Unsustainable healthcare system
  - Therapeutics cost 20-1,000 times more than prevention technologies per healthcare $$ spent
Vision: Nanovaccines will revolutionize our ability to prevent and treat disease

- Bridge groundbreaking science with novel nanoscale platform technologies
  - Science-driven, first principles paradigm for vaccine design

- Novel nanomedicine-driven platform technology for tomorrow’s vaccines
  - Inherently interdisciplinary

- Systems approach encompassing bench-to-bedside considerations from the earliest stages of conceptualization
Competitive Edge and Differentiators

- Systems approach to vaccine design
  - Design, delivery, and deployment
- Technology niche
  - Needle-free
  - Single dose
  - No refrigeration
  - Combination therapies
- Bench-to-bedside
- Partnerships with universities, government laboratories, and industry

Images: Courtesy Johns Hopkins, Ideo, Ohio State, Mystic Pharmaceuticals, and Atlantis Online
Room Temperature Nanovaccines

- Today’s vaccines need to be refrigerated
- Refrigeration is a major component of the cost and a significant logistical roadblock
- **Innovation**: exploit advances in materials science and nanotechnology to design a thermally stable subunit nanovaccine
- Nanovaccine can be stored at room temperature or higher for up to one year and still maintain efficacy

Tomorrow’s Nanovaccines?

Video courtesy of Mystic Pharmaceuticals